Abstract: The present disclosure provides, among other aspects, improved methods for the manufacture of Factor H compositions from plasma precipitation fractions. In some aspects, the methods include an improved process step for extracting Factor H from a plasma precipitate fraction with reduced co-extraction of amidolytic activities. In other aspects, the methods include a heat treatment step for reducing impurities, such as amidolytic enzymes, from a Factor H composition. In yet other aspects, the methods include improved anion exchange, heparin affinity, and/or mixed mode chromatographic enrichment of Factor H. In still other aspects, the improved methods include a combination of the individual improved process steps disclosed herein.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
January 22, 2019
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Ruth Madlener, Wolfgang Teschner, Hans-Peter Schwarz, Sonja Svatos, Azra Pljevljakovic, Lena Nitsch
Abstract: The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.
Type:
Grant
Filed:
June 21, 2013
Date of Patent:
January 8, 2019
Assignee:
Prolong Pharmaceuticals, LLC
Inventors:
Abraham Abuchowski, Glenn Kazo, Friedericke Kazo
Abstract: Compositions and methods are provided that are useful for the delivery, including transdermal delivery, of biologically active agents, such as non-protein non-nucleotide therapeutics and protein-based therapeutics excluding insulin, botulinum toxins, antibody fragments, and VEGF. The compositions and methods are particularly useful for topical delivery of antifungal agents and antigenic agents suitable for immunization. Alternatively, the composition can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.
Abstract: The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue or red blood cells with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.
Type:
Grant
Filed:
August 4, 2014
Date of Patent:
January 8, 2019
Assignee:
Prolong Pharmaceuticals, LLC
Inventors:
Abraham Abuchowski, Glenn Kazo, Friedericke Kazo, Ronald G. Jubin, Peter Joseph Buontempo
Abstract: Nucleic acid encoding modified factor VII polypeptides, vectors and cells containing the nucleic acid, uses of the nucleic acids, methods of making the encoded polypeptides, and methods of treatment are provided. The encoded modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among the encoded modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities.
Abstract: The present invention concerns lectins isolated from the fruiting body of a novel Hericium erinaceum (deposit number: KCTC 12499BP) NEU-1L strain which bind specifically to sialic acid. The invention further pertains to uses of such lectinsn abd to processes for their preparation thereby. The lectin of the present invention can be useful as an active ingredient of a composition or a kit for measuring or detecting glycoproteins, glycopeptides, glycolipids, sugar precursors or oligosaccharides containing sialic acid moieties, or further for measuring or detecting cell lines, bacteria and viruses containing sialoglycoconjugates.
Type:
Grant
Filed:
May 18, 2016
Date of Patent:
December 11, 2018
Assignee:
Korea Research Institute of Bioscience and Biotechnology
Abstract: EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
Type:
Grant
Filed:
June 3, 2016
Date of Patent:
November 20, 2018
Assignee:
University Of Pittsburgh—Of the Commonwealth System Of Higher
Abstract: The present invention relates to variants of a vitamin K-dependent serine protease of the coagulation cascade, preferably variants of factor IX (F.IX), wherein the variant is characterized in that it has clotting activity in absence of its cofactor. The present invention furthermore relates to the use of these variants for the treatment and/or prophylaxis of bleeding disorders, in particular hemophilia A and/or hemophilia B or hemophilia caused or complicated by inhibitory antibodies to F.VIII. The present invention also relates to further variants of factor IX (F.IX) which have desired properties and can, thus be tailored for respective specific therapeutic applications.
Abstract: A process for purifying fibrinogen from a fibrinogen containing source by precipitation of fibrinogen by a precipitating agent from a fibrinogen containing solution in the presence of one or more chelating agent(s) and removal of the supernatant from the fibrinogen paste, characterized in that fibrinogen is extracted from the paste forming a liquid fraction containing fibrinogen, and an undissolved residue, which is separated from the liquid.
Type:
Grant
Filed:
March 12, 2013
Date of Patent:
October 30, 2018
Assignee:
OCTAPHARMA AG
Inventors:
Petra Schulz, Werner Gehringer, Friedrich Schön, Caroline Leitinger, Jürgen Römisch, Rainer Pape
Abstract: Provided is a method of purifying human papillomavirus (HPV) L1 proteins with high purity and high efficiency. According to the purification method, a purification purity and yield of HPV L1 proteins can be considerably increased when heating/chilling is formed by treating a cell homogenate with a reducing agent. In addition, VLPs of the HPV L1 protein purified by the purification method have excellent antigenicity and immunogenicity.
Abstract: The present disclosure relates to methods of controlling the sulfide (S2?) content in systems, such as oil and gas reservoirs and pipelines, by the use of chlorine oxyanions and microorganisms with (per)chlorate-reducing activity.
Type:
Grant
Filed:
May 20, 2016
Date of Patent:
June 12, 2018
Assignee:
The Regents of the University of California
Abstract: The invention relates to a method for the production of a Factor VIII polypeptide, the method comprising the steps of a) culturing a mammalian cell expressing a Factor VIII polypeptide under conditions for expression of said Factor VIII polypeptide, said culturing conditions involving a cell culture medium comprising a C2-domain ligand, and b) isolating the expressed Factor VIII polypeptide from the mammalian cell by suitable means.
Type:
Grant
Filed:
April 30, 2008
Date of Patent:
May 29, 2018
Assignee:
Novo Nordisk A/S
Inventors:
Laust Bruun Johnsen, Ida Hilden, Gert Bolt, Thomas Dock Steenstrup
Abstract: Methods for expressing multiple proteins by constructing transformation vectors that include multiprotein expression cassettes and transforming hosts with vectors and by engineering hosts expressing multiprotein units are provided. Multiprotein units that include multiple proteins fused to modified inteins capable of effecting splicing of the multiprotein units are described. Expression cassettes that include nucleic acids encoding multiprotein units and hosts including the expression cassettes are also provided.
Type:
Grant
Filed:
October 3, 2013
Date of Patent:
May 8, 2018
Assignee:
AGRIVIDA, INC.
Inventors:
Binzhang Shen, Jason Donald, R. Michael Raab
Abstract: A mineralized collagen matrix with an intrafibrillar and/or extrafibrillar gradient of mineralization for insertion replacement is disclosed. The intrafibrillar mineralization of the collagen matrix is formed by the addition of fetuin to the simulated body fluid. The gradient of intrafibrillar mineralization may stiffen the collagen matrix and simulate a natural insertion for improved cell infiltration and regeneration.
Abstract: It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27.5 to 32.5 IU/mg and, more preferably, from 28 to 32 IU/mg.
Type:
Grant
Filed:
June 22, 2012
Date of Patent:
February 27, 2018
Assignee:
GENTRUM S.R.L.
Inventors:
Terenzio Ignoni, Vijay Kumar, Khalid Islam
Abstract: The invention relates to the use of specific protein and/or peptide fractions having a high aspartate content for regulating plasma glucose concentrations and increasing insulin sensitivity in a mammal. The invention relates to a complete food fortified with aspartate equivalents as well as a supplement rich in aspartate equivalents that is given simultaneously with or even minutes up to an hour prior to the consumption of a meal comprising glucose. The nutritional or pharmaceutical composition contains at least one protein having a high aspartate content, preferably of soy or dairy origin, which is further enriched with aspartate equivalents from another protein and/or free aspartate equivalents. The protein fraction comprises glutamate equivalents in a weight ratio of aspartate equivalents to glutamate equivalents (asp:glu) between 0.41:1 and 5:1.
Abstract: The disclosure relates to enzyme variants with improved ester synthase properties for the production of fatty acid esters. Further contemplated are recombinant host cells that express such variants, cell cultures comprising the recombinant host cells and fatty acid ester compositions produced by such recombinant host cells.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
January 30, 2018
Assignee:
REG LIFE SCIENCES, LLC
Inventors:
Andrew M. Shumaker, Bernardo M. Da Costa, Kevin Holden, Louis G. Hom, Tarah S. Baron, Noah Helman
Abstract: The present disclosure provides mutant cells for the secretion of proteins and for the degradation of lignocellulosic biomass. Methods for the use of these cells are also provided. Specifically, the utility of combined genetic deletions of ?-glucosidases and the catabolite repressor gene creA/cre-1 for protein secretion in fungal and yeast cells is disclosed.
Type:
Grant
Filed:
May 15, 2015
Date of Patent:
November 21, 2017
Assignee:
The Regents of the University of California
Inventors:
Elizabeth A. Znameroski, James H. Doudna Cate, N. Louise Glass
Abstract: The invention relates to the generation and characterization of stable MMLV reverse transcriptase mutants. The invention also discloses methods of using stable MMLV reverse transcriptase mutants.